Anti-MOG+neuromyelitis optica spectrum disorders treated with plasmapheresis

No To Hattatsu

Volumn 48, Issue 3, 2016, Pages 199-203

  Oshiro, Azusa ^a   Nakamura, Sadao ^a   Tamashiro, Kunihito ^a   Fujihara, Kazuo ^b  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZATHIOPRINE; METHYLPREDNISOLONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PREDNISOLONE; AUTOANTIBODY;

APPENDICITIS; ARTICLE; CASE REPORT; CHILD; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMA EXCHANGE; PLASMAPHERESIS; SCHOOL CHILD; VIRUS INFECTION; VISUAL ACUITY; DRUG PULSE THERAPY; IMMUNOLOGY; NEUROMYELITIS OPTICA; TREATMENT OUTCOME;

AUTOANTIBODIES; AZATHIOPRINE; CHILD; HUMANS; MALE; METHYLPREDNISOLONE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; PLASMAPHERESIS; PREDNISOLONE; PULSE THERAPY, DRUG; TREATMENT OUTCOME;

EID: 84979093809     PISSN: 00290831     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805-15.
2. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendeations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261:1-16.
3. Reindl M, Di Pauli F, Rostásy K, Berger T. The Spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9:455-61.
4. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82:474-81.
5. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71:276-83.
6. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183:4067-76.
7. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-9.
8. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 2012; 3:58-73.
9. Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica MOG-IgG causes reversible lesion in mouse brain. Acta Neuropathol Commun 2014; 2:35.
10. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19:1261-7.